Macular Degeneration Supplements: What AREDS2 Actually Found – Agape Nutrition
Left Continue shopping
Your Order

You have no items in your cart

Reading glasses, dark leafy greens and an amber bottle of macular degeneration supplements on cream linen

Macular Degeneration Supplements: What AREDS2 Actually Found

If you have been told you have drusen, or intermediate age-related macular degeneration, you have probably stood in the eye supplement aisle since. The bottles use the same words and the prices run high. This guide settles which bottle matches the formula that was studied, and what that formula can and cannot do.

Table of Contents

What Macular Degeneration Supplements Actually Means

The phrase has a specific meaning in the research, even though the shelf does not. When an eye doctor says macular degeneration supplements, they usually mean the AREDS2 formula: six nutrients at doses tested in a large clinical trial.

An AREDS2 supplement is not a generic eye vitamin. It is a matched combination of vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper.

The marketing uses softer language. Macular support supplements and eye vitamins for macular degeneration can describe almost anything, including a multivitamin with a token amount of lutein. The front of the bottle does not tell you which one you are holding. The supplement facts panel does.

The formula is public, so matching it is arithmetic.

What the Macula Does, and Why Stage Changes Everything

The macula is the small area at the center of the retina, and it handles reading, faces, and driving. When it loses cells, the loss lands in the middle of the visual field. It also does the heavy lifting during long screen sessions, which is why eye strain from screens is a separate question from AMD.

AMD comes in two forms. Dry AMD involves drusen, deposits under the retina, and it usually progresses slowly. Wet AMD involves abnormal blood vessels under the retina, and it can change vision quickly.

Stage matters more than any label claim. Early AMD means small drusen. Intermediate AMD means more or larger drusen, often with pigment changes. Late AMD means geographic atrophy or neovascular disease.

The trials that built the formula enrolled people at a specific stage, and that is where the evidence lives.

AMD is common. CDC estimates put any AMD at 19,828,000 US adults aged 40 and older in 2019, or 12.6 percent, with vision-threatening AMD at 0.94 percent.

Cross-section illustration of a human eye with the macula highlighted, for macular degeneration supplements
The macula sits at the center of the retina, the region these nutrients are studied for.

The Two Trials That Matter

Two trials carry almost all the weight. AREDS, published in 2001, tested antioxidants plus zinc. AREDS2, published in 2013, tested lutein and zeaxanthin and omega-3 fats, and it removed beta-carotene.

AREDS enrolled 3,640 people for an average of 6.3 years. Antioxidants plus zinc was associated with lower odds of progression to advanced AMD, with an odds ratio of 0.72 (99 percent CI 0.52 to 0.98). Zinc alone came in at 0.75 (0.55 to 1.03), and antioxidants alone at 0.80 (0.59 to 1.09).

It also showed lower odds of losing 15 or more letters of acuity, at 0.73 (0.54 to 0.99). In the higher-risk subgroup it reached 0.66 (0.47 to 0.91).

The formula performed best in the people with the most to lose, which is why stage keeps coming up.

What AREDS2 Actually Found

AREDS2 enrolled 4,203 people and followed them for a median of 5 years. The five-year probability of progression to advanced AMD was 31 percent in the placebo group, 29 percent with lutein plus zeaxanthin, 31 percent with DHA plus EPA, and 30 percent with the combination. The trial analyzed progression by eye.

The hazard ratios followed the same pattern. Lutein plus zeaxanthin came in at 0.90 (98.7 percent CI 0.76 to 1.07), DHA plus EPA at 0.97 (0.82 to 1.16), and the combination at 0.89 (0.75 to 1.06).

None of the primary comparisons reached statistical significance. That is the finding most marketing leaves out.

The figure of about 28 percent lower odds of progression, often rounded to 25 percent in consumer summaries, belongs to the original AREDS combination, not to the AREDS2 primary result. The result was a modest signal that did not clear the trial's own bar, so the honest effect is smaller than the ads suggest.

The 10-Year Follow-Up and the Beta-Carotene Problem

AREDS2 kept following its participants. At 10 years, late AMD progression was lower with lutein and zeaxanthin than with none, at a hazard ratio of 0.91 (0.84 to 0.99). Against beta-carotene, the hazard ratio was 0.85 (0.73 to 0.98).

Within the beta-carotene subgroup, lutein and zeaxanthin showed the largest difference, at 0.80 (0.68 to 0.92).

An earlier secondary analysis pointed the same way. Lutein and zeaxanthin versus beta-carotene had a hazard ratio of 0.82 (0.69 to 0.96) for late AMD and 0.78 (0.64 to 0.94) for neovascular AMD.

Why beta-carotene was removed

AREDS2 reported 23 lung cancers (2.0 percent) with beta-carotene against 11 (0.9 percent) without it, nominal P = .04, mostly in former smokers. At 10 years the lung cancer odds ratio was 1.82 (1.06 to 3.12) with beta-carotene and 1.15 (0.79 to 1.66) with lutein and zeaxanthin.

That is why the current formula has no beta-carotene, and why smokers and former smokers should check for it specifically.

What the wider reviews add

A 2023 Cochrane review included 26 studies covering 11,952 people. In its antioxidant-versus-control analysis, which drew on 3 studies and 2,445 participants, the odds ratio for progression to late AMD was 0.72 (0.58 to 0.90), moderate certainty. Its lutein and zeaxanthin analysis rested on one trial, AREDS2, with RR 0.94 (0.87 to 1.01), low certainty.

In a 2024 post hoc subgroup analysis, lutein and zeaxanthin were associated with slower progression toward the fovea in noncentral geographic atrophy, 80.1 versus 114.4 micrometers per year (P = .011), though area-based progression did not differ (P = .64).

Who the Formula Is For, and Who It Is Not For

The formula was studied in people with intermediate AMD in one or both eyes, or late AMD in one eye. That is the group the trials enrolled.

It is not for everyone else. The National Eye Institute is direct: early AMD does not benefit, and late AMD in both eyes probably will not benefit either. The Macular Disease Foundation Australia lists the same exclusions: no AMD, early AMD only, and late AMD in both eyes.

The American Academy of Ophthalmology adds that people with a lot of drusen are the most likely to benefit.

If you have wet AMD, the treatment is anti-VEGF injection therapy from a retina specialist. A supplement is not a substitute for that treatment.

If you have early AMD, the formula is not a prevention strategy. It was not studied for that.

The Six Ingredients and the Doses That Were Studied

The AREDS2 formula is short enough to memorize. Here are the doses that were studied.

Nutrient Studied dose What to check on the label
Vitamin C 500 mg Ascorbic acid or ascorbate
Vitamin E 400 IU Compare in IU, not mg
Lutein 10 mg From marigold extract
Zeaxanthin 2 mg 1,000 mcg equals 1 mg
Zinc 80 mg in the standard formula, 25 mg tested in AREDS2 Elemental zinc
Copper 2 mg Any well-absorbed form, included to balance zinc

Those six nutrients, at those doses, are the formula. Everything else on a label is either supporting the dose or getting in the way of it.

Do lutein and zeaxanthin build macular pigment?

Lutein and zeaxanthin concentrate in the macula, where they form part of the macular pigment. A 2024 network meta-analysis of randomized trials found that antioxidant formulas containing both increased macular pigment optical density, and a 2026 meta-analysis of 9 trials found lutein-based supplements were associated with improvements in macular pigment and visual acuity, mainly in early AMD.

That is a measured effect, but it is not the same as preventing progression to late AMD, and it does not change the stage guidance above.

For the vitamin E line in particular, the vitamin E supplement guide covers which form to look for and how the IU dose compares with milligrams.

The Zinc Question: 80 mg or 25 mg

AREDS2 tested 25 mg of zinc against 80 mg, and the difference was negligible. The hazard ratio for progression with 25 mg versus 80 mg was 1.04 (0.94 to 1.14), which means the lower dose did not perform meaningfully worse.

Twenty-five milligrams performed no worse than 80 mg in the AREDS2 zinc comparison, and it avoids the higher dose that is linked to more stomach upset.

The 80 mg dose comes from the original AREDS formula. Higher zinc is linked to more gastrointestinal upset and to copper deficiency, which is why the studied formula includes 2 mg of copper.

People with kidney disease should be careful with high zinc intake. Anyone taking a separate zinc product should add up the total. If you are choosing a standalone zinc, how to pick the best form of zinc covers the difference between glycinate and picolinate.

What the Formula Cannot Do

The list is short and worth reading twice.

  • It does not cure AMD.
  • It does not reverse vision loss that has already happened.
  • It does not prevent AMD from starting or from moving from early to intermediate.
  • It is not a treatment for wet AMD.
  • It does not replace anti-VEGF injections or regular eye exams.
  • It does not restore vision that late AMD has already taken.

The formula supports macular nutrition at one specific stage of a specific disease, and that is the whole of its job.

Anything a label claims beyond that is not supported by the trials in this guide.

How to Read an Eye Supplement Label

  1. Find the serving size. It is the first line of the panel, and it is often two capsules, not one.
  2. Divide the listed dose by the number of capsules in a serving. If the label says 10 mg of lutein per two capsules, one capsule gives you 5 mg.
  3. Compare each nutrient against the studied dose: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 25 mg or 80 mg, copper 2 mg.
  4. Check for beta-carotene. If it is listed and you smoke or used to smoke, put the bottle down.

A bottle can say 10 mg of lutein and still deliver 5 mg per capsule. That is the most common arithmetic trap in the category.

Two more checks matter. Watch the units, because zeaxanthin is often listed in micrograms and 1,000 mcg is 1 mg. Watch for a proprietary blend, because a blend can legally hide each ingredient's dose.

Blank supplement label, magnifying glass and checklist, used to check eye vitamins for macular degeneration
A blank label is the starting point: compare the serving size and each dose against the studied AREDS2 amounts.

What the Label Research Found

A 2026 review in Seminars in Ophthalmology checked what over-the-counter macular supplements sold in the UK actually contain. Most deviated from the AREDS2 formula.

The average shortfalls were large. Vitamin C was 52.3 percent lower than the studied dose, vitamin E was 61.2 percent lower, and zinc was 40.1 percent lower. Only a small subset matched both the composition and the dose.

The average bottle in that review was not close to the formula on its label.

That is a category-wide formulation problem, not a reason to distrust every brand.

Diet, Smoking, Blood Pressure, and Eye Exams

No supplement outruns the basics.

A 2025 meta-analysis of risk factors put smoking at an odds ratio of 1.86 (1.33 to 2.60), hypertension at 1.24 (1.09 to 1.40), cardiovascular disease at 1.44 (1.11 to 1.87), and diabetes at 1.44 (1.30 to 1.60).

Diet shows a similar signal. A 2025 meta-analysis of the Mediterranean pattern found an odds ratio of 0.66 (0.54 to 0.81) in case-control studies and a hazard ratio of 0.77 (0.67 to 0.88) for progression in prospective cohorts. Cross-sectional studies showed no association, at 0.96 (0.83 to 1.11).

Eye exams are the other half. A dilated exam finds changes before you feel them, and an Amsler grid at home can catch new distortion between visits.

Stop smoking, control blood pressure, eat well, and keep the eye exam. The bottle is the smallest lever of the four.

Overhead still life of spinach, kale, corn, eggs and salmon, whole-food sources of lutein and zeaxanthin
Lutein and zeaxanthin occur naturally in leafy greens, corn, egg yolks and orange produce.

Do Omega-3s Help?

The AREDS2 omega-3 arm was null. DHA plus EPA produced 31 percent progression, the same as placebo, with a hazard ratio of 0.97 (0.82 to 1.16).

There is no good basis for taking fish oil to slow AMD progression. That is the honest reading of the largest trial that tested it.

A 2026 pilot study asked whether omega-3 changes how well lutein and zeaxanthin are absorbed. At 900 mg per day, it did not significantly change bioavailability or oxidative stress markers. Treat it as a hint.

A DHA-focused fish oil may still be chosen for other reasons, but it is not a substitute for the AREDS2 formula. If you do buy one, the best form of fish oil compares triglyceride, ethyl ester, and monoglyceride.

Safety and Interactions

The formula has real caveats.

  • Stomach upset. Zinc and vitamin C can cause nausea or loose stools. Take it with food.
  • Copper and zinc. High zinc can lead to copper deficiency, which is why the formula includes 2 mg of copper. Do not stack a separate zinc product.
  • Vitamin E and bleeding. Vitamin E at 400 IU can increase bleeding risk, particularly with warfarin or other anticoagulants. Tell your prescriber.
  • Medication interactions. Blood thinners and some blood pressure medications can interact. A pharmacist can check the list quickly.
  • Kidney disease. High zinc deserves caution in kidney disease.
  • Smokers and former smokers. Choose a formula with no beta-carotene.

Tell your eye doctor and your pharmacist everything you take, including the eye formula. That habit catches most of the risk.

When to Call a Doctor

Some vision changes are not a supplement question.

Call your eye doctor the same day if you notice:

  • A sudden change in central vision
  • Straight lines that look wavy or bent
  • A new dark spot in the center of your vision
  • A sudden loss of vision in one eye
  • A burst of new floaters or flashes of light

A supplement is never the right response to a sudden vision change. Those symptoms can signal wet AMD or another condition that needs treatment quickly.

Do not stop or change a prescribed eye treatment on your own. Ask the clinician who prescribed it.

Two related guides cover the slower, non-urgent questions: supplements for dry eyes and supplements for eye floaters. Neither is a substitute for the exam above.

A Practical Buying Checklist

  1. Confirm your stage. The formula was studied in people with intermediate AMD in one or both eyes, or late AMD in one eye.
  2. Match all six doses: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 25 mg or 80 mg, copper 2 mg.
  3. Do the serving arithmetic. Two capsules per serving means half the dose per capsule.
  4. Check for beta-carotene and avoid it if you smoke or used to smoke.
  5. Look for third-party testing you can verify.
  6. Take it with a meal that contains fat. In a 2023 trial using a carotenoid-rich salad, bioaccessibility was 24.0 percent with olive oil versus 14.9 percent with coconut oil, and the plasma carotenoid response was higher with olive oil.
  7. Add one product at a time, give it three months, and judge it at your next eye exam.

If a bottle fails step two or step three, nothing else on the label rescues it.

What We Recommend

These are formulas we carry whose labels we can compare against the nutrient profile discussed above. None of them is a treatment for AMD.

Pure Encapsulations EyeProtect Basics 60 Capsules

A close match to the AREDS2 formula. Per two capsules it supplies the studied 500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, and 2 mg copper, plus 25 mg zinc, the lower of the two zinc doses AREDS2 tested.

$29.20

Pure Encapsulations EyeProtect Basics without Zinc 60 Capsules

The same formula without zinc, for someone already taking zinc separately or advised to keep zinc low.

$28.00

Nordic Naturals ProDHA Eye 60 and 120 Softgels

A carotenoid plus DHA option that supplies 20 mg lutein, 4 mg zeaxanthin, and 1,460 mg total omega-3 per two softgels, not a replacement for the full AREDS2 formula.

$53.25 for 60 softgels, $96.30 for 120

XYMOGEN I-Sight 60 Capsules

A broader ocular antioxidant formula built around bilberry, taurine, NAC, alpha-lipoic acid, lutein, and lycopene.

$89.99

Confirm with your eye doctor that a supplement is appropriate for your stage before you start one.

Frequently Asked Questions

Do macular degeneration supplements actually work?

For intermediate AMD, the support is modest and the trials disagree on how much. The primary analysis missed statistical significance; the 10-year follow-up found a small reduction with lutein and zeaxanthin. It does not restore vision that is already lost.

What is the difference between AREDS and AREDS 2 vitamins?

AREDS2 removed beta-carotene and added lutein and zeaxanthin. It also found no meaningful difference between 25 mg and 80 mg of zinc. Most current formulas use the AREDS2 ingredient list, but many do not match its doses.

Can I take a multivitamin instead?

Usually not. A multivitamin rarely carries 500 mg of vitamin C, 400 IU of vitamin E, 10 mg of lutein, and 2 mg of zeaxanthin in one serving. Check the panel against the six doses.

What about smokers and former smokers?

Choose the AREDS2 version, which has no beta-carotene. Beta-carotene was linked to a higher lung cancer rate in the trial, mostly in former smokers. Check that line specifically.

Are lutein and zeaxanthin for macular degeneration worth taking?

For intermediate AMD, they are part of the studied formula. For early AMD, the evidence does not support starting them, and the National Eye Institute says early AMD does not benefit. Ask your eye doctor about your stage.

Do omega-3 supplements help macular degeneration?

The AREDS2 omega-3 arm was null, with 31 percent progression in both the DHA plus EPA and placebo groups. Fish oil is not a substitute for the AREDS2 formula.

Can I take AREDS2 vitamins with my medications?

It depends on the medication, so check first. Vitamin E at 400 IU can increase bleeding risk with warfarin and other anticoagulants, and high zinc matters in kidney disease. A pharmacist can review the full list.

References

  1. Age-Related Eye Disease Study Research Group. "A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8." Archives of Ophthalmology. 2001. https://pubmed.ncbi.nlm.nih.gov/11594942/
  2. Age-Related Eye Disease Study 2 Research Group. "Lutein plus zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 randomized clinical trial." JAMA. 2013. https://pubmed.ncbi.nlm.nih.gov/23644932/
  3. Age-Related Eye Disease Study 2 Research Group. "Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3." JAMA Ophthalmology. 2014. https://pubmed.ncbi.nlm.nih.gov/24310343/
  4. Chew EY, et al. "Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28." JAMA Ophthalmology. 2022. https://pubmed.ncbi.nlm.nih.gov/35653117/
  5. Keenan TDL, et al. "Oral antioxidant and lutein/zeaxanthin supplements slow geographic atrophy progression to the fovea in age-related macular degeneration." Ophthalmology. 2024. https://pubmed.ncbi.nlm.nih.gov/39025435/
  6. Evans JR, Lawrenson JG. "Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration." Cochrane Database of Systematic Reviews. 2023. https://pubmed.ncbi.nlm.nih.gov/37702300/
  7. Beckers D, et al. "Beyond the label: inconsistencies in AREDS2 eye supplements and a call for standardisation." Seminars in Ophthalmology. 2026. https://pubmed.ncbi.nlm.nih.gov/41108153/
  8. Kalu KA, et al. "The relative bioavailability of lutein and zeaxanthin in the presence of omega-3 supplements and their effect on oxidative stress levels in humans: a pilot study." Nutrients. 2026. https://pubmed.ncbi.nlm.nih.gov/42356301/
  9. Yao Y, et al. "Effects of dietary fat type and emulsification on carotenoid absorption: a randomized crossover trial." American Journal of Clinical Nutrition. 2023. https://pubmed.ncbi.nlm.nih.gov/36921903/
  10. Centers for Disease Control and Prevention. "Age-related macular degeneration prevalence estimates." Released 2022. https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html
  11. Babaker R, et al. "Risk factors for age-related macular degeneration: updated systematic review and meta-analysis." Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/39993131/
  12. Marques-Couto P, et al. "Mediterranean diet on development and progression of age-related macular degeneration: systematic review and meta-analysis of observational studies." Nutrients. 2025. https://pubmed.ncbi.nlm.nih.gov/40292456/
  13. Wang WX, et al. "From supplements to sight: quantifying the impact of lutein and carotenoid on age-related macular degeneration, a systematic review and meta-analysis of randomized controlled trials." Journal of Ophthalmology. 2026. https://pubmed.ncbi.nlm.nih.gov/42028334/
  14. Hu W, et al. "Effect of antioxidant supplementation on macular pigment optical density and visual functions: a systematic review and network meta-analysis of randomized controlled trials." Advances in Nutrition. 2024. https://pubmed.ncbi.nlm.nih.gov/38582248/
  15. National Eye Institute. "Nutritional supplements for age-related macular degeneration." Accessed 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration/nutritional-supplements-age-related-macular-degeneration
  16. American Academy of Ophthalmology. "Vitamins for age-related macular degeneration." Accessed 2026. https://www.aao.org/eye-health/diseases/vitamins-amd
  17. Macular Disease Foundation Australia. "Supplements for AMD." Accessed 2026. https://www.mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/supplements-for-amd/

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.